LPL Financial LLC Grows Position in Haemonetics Co. (HAE)

Share on StockTwits

LPL Financial LLC boosted its holdings in Haemonetics Co. (NYSE:HAE) by 4.0% in the 4th quarter, Holdings Channel reports. The firm owned 11,644 shares of the medical instruments supplier’s stock after purchasing an additional 448 shares during the period. LPL Financial LLC’s holdings in Haemonetics were worth $1,165,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also added to or reduced their stakes in the company. DekaBank Deutsche Girozentrale raised its position in Haemonetics by 18.7% in the 3rd quarter. DekaBank Deutsche Girozentrale now owns 13,749 shares of the medical instruments supplier’s stock valued at $1,513,000 after purchasing an additional 2,165 shares during the last quarter. HealthCor Management L.P. purchased a new stake in Haemonetics in the 3rd quarter valued at $34,287,000. LSV Asset Management purchased a new stake in Haemonetics in the 3rd quarter valued at $294,000. Vanguard Group Inc raised its position in Haemonetics by 1.9% in the 3rd quarter. Vanguard Group Inc now owns 5,619,707 shares of the medical instruments supplier’s stock valued at $643,906,000 after purchasing an additional 107,357 shares during the last quarter. Finally, Riverhead Capital Management LLC raised its position in Haemonetics by 27.8% in the 3rd quarter. Riverhead Capital Management LLC now owns 5,971 shares of the medical instruments supplier’s stock valued at $684,000 after purchasing an additional 1,300 shares during the last quarter. Hedge funds and other institutional investors own 98.13% of the company’s stock.

Several analysts recently commented on HAE shares. Barrington Research upped their price target on shares of Haemonetics to $112.00 and gave the company a “positive” rating in a research report on Wednesday, February 6th. ValuEngine downgraded shares of Haemonetics from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 5th. Finally, Zacks Investment Research downgraded shares of Haemonetics from a “buy” rating to a “sell” rating in a research report on Tuesday, January 8th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $119.75.

In related news, Director Ronald G. Gelbman sold 8,196 shares of the stock in a transaction dated Friday, February 15th. The shares were sold at an average price of $86.52, for a total value of $709,117.92. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Michelle L. Basil sold 391 shares of the stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $83.57, for a total transaction of $32,675.87. The disclosure for this sale can be found here. Over the last three months, insiders sold 8,703 shares of company stock worth $751,488. 1.04% of the stock is owned by corporate insiders.

Shares of Haemonetics stock opened at $86.75 on Friday. The firm has a market cap of $4.43 billion, a price-to-earnings ratio of 46.39, a PEG ratio of 2.80 and a beta of 0.89. The company has a quick ratio of 1.64, a current ratio of 2.44 and a debt-to-equity ratio of 0.51. Haemonetics Co. has a one year low of $70.86 and a one year high of $117.56.

Haemonetics (NYSE:HAE) last announced its quarterly earnings data on Tuesday, February 5th. The medical instruments supplier reported $0.63 EPS for the quarter, topping the Zacks’ consensus estimate of $0.59 by $0.04. The company had revenue of $247.36 million during the quarter, compared to the consensus estimate of $250.12 million. Haemonetics had a net margin of 4.84% and a return on equity of 17.05%. Haemonetics’s quarterly revenue was up 5.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.62 EPS. On average, equities research analysts forecast that Haemonetics Co. will post 2.33 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This news story was first reported by Ticker Report and is the property of of Ticker Report. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this news story can be read at https://www.tickerreport.com/banking-finance/4223370/lpl-financial-llc-grows-position-in-haemonetics-co-hae.html.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.

See Also: Marijuana Stocks Investing Considerations

Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Co. (NYSE:HAE).

Institutional Ownership by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Head to Head Analysis: Key Energy Services  vs. RPC
Head to Head Analysis: Key Energy Services vs. RPC
Colu Local Network  Price Up 4.3% This Week
Colu Local Network Price Up 4.3% This Week
Gladstone Capital Co.  Expected to Announce Earnings of $0.21 Per Share
Gladstone Capital Co. Expected to Announce Earnings of $0.21 Per Share
Bitcoin Gold Reaches Market Capitalization of $392.92 Million
Bitcoin Gold Reaches Market Capitalization of $392.92 Million
Quanta Services Inc  Receives $42.80 Average PT from Brokerages
Quanta Services Inc Receives $42.80 Average PT from Brokerages
PHI Token  Price Hits $0.15 on Major Exchanges
PHI Token Price Hits $0.15 on Major Exchanges


© 2006-2019 Ticker Report